Purpose: To investigate whether glucagon-like peptide-1 receptor agonists are protective against retinal vascular occlusions. Methods: Using a large aggregated, de-identified electronic health records data platform in the United States, patients with type 2 diabetes ages ≥18 years prescribed glucagon-like peptide-1 receptor agonists or non-glucagon-like peptide-1 receptor agonists (controls) and having ophthalmology follow-up of at least… Continue reading The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Risk of Retinal Vascular Occlusions
Tag: GLP
Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta-analysis
AimsAdjunctive therapies to insulin for type 1 #diabetes mellitus (T1DM), including glucagon-like peptide-1 receptor agonists ( #GLP-1RAs ) and sodium–glucose cotransporter-2 inhibitors ( #SGLT2is ), may improve glycaemic control and reduce insulin requirements; however, safety concerns remain, particularly for diabetic ketoacidosis (DKA).Materials and MethodsPubMed, Ovid MEDLINE, Embase, Web of Science, Scopus and the Cochrane Library… Continue reading Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta-analysis
